Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.

@article{Dakhil2014PhaseIS,
  title={Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma.},
  author={Shaker R. Dakhil and Robert Hermann and Marshall T. Schreeder and Stephanie A. Gregory and Marc Monte and Kevin S Windsor and Deborah Hurst and Akiko Chai and M. Quinn Brewster and Paul Richards},
  journal={Leukemia & lymphoma},
  year={2014},
  volume={55 10},
  pages={2335-40}
}
This phase III, multicenter, single-arm trial investigated the impact of 90 min rituximab infusions on infusion-related reactions (IRRs) in patients with untreated diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). Patients received six or eight cycles of rituximab plus cyclophosphamide, vincristine, doxorubicin and prednisone for DLBCL or plus cyclophosphamide, vincristine and prednisolone for FL. A total of 425 patients received the first rituximab infusion per standard… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Similar Papers

Loading similar papers…